Particle Sciences Receives Patent for its Surface Arrayed Therapeutics Drug Delivery Platform

Particle Sciences has received a Notice of Allowance for composition and use of the technology incorporated into its SATx platform. The SATx platform covers several structures that combine nanoparticles with surface bound large molecules. The technology has utility in applications ranging from oncology to vaccines.

According to Mark Mitchnick, CEO: "Particle Sciences has been steadily building our drug delivery intellectual property portfolio and this is one more significant step. Recently we presented SATx at the American Chemical Society, which was very well received. Using this platform we are able to offer our clients a real alternative to typical ADC approaches, one that can be rapidly prototyped and does not require the use on any new chemical entities."

Robert Becker, Vice President Biopharmaceutical Sales and Business Development, added: "Particle Sciences has made a significant investment in both the formulation and analytic support of biologics. The SATx technology is a disruptive nanoparticle platform that gives our clients new options for improving the potency, safety and utility of both large and small molecule therapeutics that can’t be found elsewhere. For clients looking to leverage their new biopharmaceuticals and vaccines, and those seeking to develop "bio-betters" the SATx platform should be seriously considered and evaluated."